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Background: Infectious diseases of the airways are a major health care problem world wide. New treatment
strategies focus on employing the body's immune system to enhance its protective capacities during airway
disease. One source for immune-competent cells is the pleural space, however, its immune-physiological function
remains poorly understood. The aim of this study was to develop an experimental technique in rodents that allows
for an in vivo analysis of pleural space immune cells participating in the host defense during airway disease.
Methods: I developed an easy and reliable technique that I named the “InterCostal Approach of the Pleural Space”
(ICAPS) model that allows for in vivo analysis of pleural space immune cells in rodents. By injection of immune cell
altering fluids into or flushing of the pleural space the immune response to airway infections can be manipulated.
Results: The results reveal that (i) the pleural space cellular environment can be altered partially or completely as
well as temporarily or permanently, (ii) depletion of pleural space cells leads to increased airway inflammation
during pulmonary infection, (iii) the pleural space contributes immune competent B cells during airway
inflammation and (iv) inhibition of B cell function results in reduced bacterial clearance during pneumonia.
Conclusion: As the importance for in-depth knowledge of participating immune cells during health and disease
evolves, the presented technique opens new possibilities to experimentally elucidate immune cell function,
trafficking and contribution of pleural space cells during airway diseases.
Keywords: ICAPS, Pleural space, Immune cell trafficking, Airway inflammationBackground
Lower respiratory infections are the worlds third leading
cause of death (WHO statistics 2012) and a major health
care problem world wide [1,2]. Reasons for this are the
increasing elderly population, the increase in the number
of immunocompromised patients and the increase of
infections with multi-resistant microbes which leads
altogether to an increasing burden of the global health
care system [3-8]. To counteract this process, a better
understanding of the involved immune-physiological
processes during pulmonary infections is needed to
design more individualized approaches to the underlying
disease.
One source for immune-competent cells is the pleural
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unless otherwise stated.pleura - each consisting of a monolayer of mesothelial
cells. It contains several different leukocytes including
neutrophils, monocytes and macrophages, T cells and B
cells [9,10]. Their involvement during airway infection
have been shown recently by transmigration of leuko-
cytes into the pleural space during airway inflammation
as well as regulation of neutrophilic influx by pleural
space macrophages [11,12]. However, the involvement of
pleural space immune cells during other infectious, ma-
lignant, autoimmune or allergic disease is still insuffi-
ciently understood.
For example, after performing thoracic surgery pa-
tients are regularly treated with chest tubes [13,14]. The
purpose is to evacuate wound fluid and air from the
thorax and to realign the lungs [15-17] by restoring
negative pressure in the pleural space [18,19]. A side
effect of this procedure is the constant drainage of im-
mune competent cells from the pleural space. Recent
research indicates an increased risk for pulmonarys an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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treatment [20]. I therefore sought to develop an experi-
mental technique that allows to elucidate the in vivo im-
munological contribution of pleural space cells during
health and disease.
Two major obstacles have stood in the way of study-
ing the immunological function of the pleural space of
rodents. (i) The size: the space between the parietal
and visceral pleurae is narrow, offering only a small
area for manipulation. (ii) The function: during respir-
ation, the pleural space must maintain negative pres-
sure to align the lungs with the chest wall. In a typical
approach to the pleural space investigators tend to
puncture the diaphragm, which disrupts the negative
pressure and causes a fatal pneumothorax. For this rea-
son I invented a new technique that I named the
“InterCostal Approach of the Pleural Space” (ICAPS)
model that bypasses the diaphragm to perform in vivo
analysis in rodents.
First, I mimicked the effects of chest tube treatment
(which causes a drainage of immune competent cells
from the pleural space) by flushing the pleural space
using ICAPS and investigated the effects on the re-
population of the pleural space cellular environment.
Second, I tested if the pleural space cellular environ-
ment can be altered temporarily, permanently, par-
tially or completely by using ICAPS and third if this




C57BL/6 J (wt) were used in this study. All mice were
8–20 weeks of age at the time of sacrifice. All protocols
were approved by the Animal Review Committee (AK
24–9168.11-1/2014-2) at the University Hospital Carl
Gustav Carus, Technische Universität Dresden, the Gov-
ernment of Saxony, Germany, and the Animal Review
Committee at Massachusetts General Hospital.
InterCostal Approach of the Pleural Space
To overcome the physical obstacles, and to begin explor-
ing the immunological function and contribution of
pleural leukocytes in vivo, I developed the “InterCostal
Approach of the Pleural Space” (ICAPS) method. ICAPS
relies on the intercostal insertion of a catheter-syringe at
a low angle to the organism’s thorax. The strategy by-
passes the diaphragm and, because of the angle, reduces
the risk of puncturing the lung. When the catheter is re-
moved, the intercostal muscles seal the puncture canal
and prevent a pneumothorax (Figure 1, Additional file 1:
Video). The procedure time is 5–7 minutes. In the
following, the tools and the procedure are described
step-by-step.Mice and reagents
– Male or female mice (25–30 g) or Long–Evans rats
(300–325 g)
– Isoflurane (1.5 - 2.0% (mice), 2.0 - 3.0% (rats) mg
per kg body weight for maintaining the anesthesia
during the procedure)
– Buprenorphin (0.05 mg per kg body weight)
– Sterile alcohol prep pads
– Sterile saline solution (0.9% (wt/vol) saline)
Equipment





– Black-braided silk non-absorbable surgical spool
suture 5–0 (mice)/4-0 (rats)
– Surgical instruments: dissection scissors, anatomical
forceps, microsurgical scissors, and microsurgical
needle holder
– Polyethylene catheter (Becton Dickinson,
Intramedic, #427401, I.D. 0.28 mm) attached to a 29
gauge 0.3 ml syringe. The tip of the catheter needs
to be sharpened with an approximately 30° angle by
using the microsurgical scissors (Figure 1A)
– For protection of the operator and to keep the
surgical field aseptic the use of gloves, face mask and
surgical gown is recommended
Step-by-step procedure
a. Preparation of 3 pieces of fixation tape and
installation of an accurate light source
b. Control of the anesthesia chamber and anesthesia of
the rodent
c. Positioning of the rodent on the left side and
fixation of the legs and the arms with the fixation
tape (1) for a right antero-lateral thoracic incision
d. Cleaning of the incision area of the thorax with
alcohol tips
e. Performing of a 4 cm long incision on the right
antero-lateral thorax with the dissection scissors
until reaching the thoracic wall; the attached
muscles should not be damaged (2 and 3)
f. Aspiration of the fluid or cells into the catheter syringe
g. By using the microsurgical needle holder, the
sharpened tip of the catheter should be guided
tangentially into the intercostal space; when the
catheter is placed in the correct position it should
follow the movements of the mouse thorax during
breathing (4)
Table 1 Analysis of complications during ICAPS
Complication n %
(i) Lung injury 4/110 3,6
(ii) Pneumothorax 2/110 1,8
(iii) Bleeding 1/110 0,9
By performing the ICAPS procedure different complications can occur. (i) In 4
of 110 cases (3.6%) lung injury occurred. (ii) In 2 of 110 cases (1.8%) a
pneumothorax was detected. (iii) In 1 of 110 cases (0.9%) an intra-pleural
bleeding was observed. The table shows the analysis of all performed ICAPS







Figure 1 The “InterCostal Approach of the Pleural Space” (ICAPS) model. (A) Shown is a 0.3 ml syringe connected to a 10 cm long
polyethylene catheter with a sharpened tip which is the tool to approach the pleural space of rodents. (B) Illustration of the ICAPS model: (1)
Mouse under isoflurane anesthesia and fixated with tape. (2) 4 cm long right antero-lateral thoracic incision. (3) Illustration of lung and liver seen
through the thorax. (4) Insertion of the polyethylene catheter into the pleural space in a low angle to avoid damaging the lung or causing a
pneumothorax. (5) Injection of the blue dye reveals the correct position of the catheter. After removal of the catheter, the skin is closed by 5/0
Ethilon suture and the mouse recovers quickly. Buprenorphin is administered i.p.. (6) To reveal the accuracy of this procedure the mouse
diaphragm was explored via an abdominal incision after the procedure was performed. The blue dye can be seen through the diaphragm.
(7) The mouse recovers quickly after the procedure. (8) No lung damage is observed. (9) The blue dye was recovered by flushing the pleural
space revealing the correct position of the catheter.
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i. Removing the catheter tangentially in one motion
j. CAUTION: a sub-diaphragm view was performed to
illustrate the successful procedure. This shouldn’t be
done during a planned experiment (6)
k. Performing wound closure with the a continuous
suture
l. Removing of the fixation tape
m.After i.p. pain medication (buprenorphin, 0.1 mg/kg)
the rodent can be re-positioned into the cage (7)
n. CAUTION: To test for the successful procedure in
this demonstration case the mouse was sacrificed.
The lungs showed no damage (8) and the blue dye
could be retrieved completely (9)
Procedure tips and troubleshooting
After positioning the rodent for the right antero-lateral
incision, precise preparation of the thoracic wall without
harming the thoracic muscles is essential. This reduces
the risk for a pneumothorax after the catheter is re-
moved as the overlaying muscles seal the puncturing
canal. Undamaged muscles also help to ensure a faster
recovery of the rodent. In the case of vessel injury and
inadequate view on the thoracic wall, a gauze pad can be
placed into the wound area. After 3 minutes the bleed-
ing usually stops. Insertion of the catheter into the
pleural space is the most important step during the pro-
cedure. The insertion should be performed in a quick,
single motion. For improved control of this motion, the
index finger of the left hand should stabilize the rodents
right thorax while the catheter is held with the micro-
surgical needle holder and guided into the correctposition (Figure 1B, Additional file 1: (video)). After in-
sertion, the position of the catheter can be monitored by
its movements which are aligned with the breathing
excursions. If the experiment requires flushing of the
pleural space the flushing solution should be injected
slowly. This minimizes the risk of respiratory insuffi-
ciency. After 30 seconds the fluid should be removed en-
tirely. This process needs to be repeated twice to
efficiently deplete the cellular compartments from the
pleural space. When removing the catheter, the thorax
should be stabilized as well. The mouse should be moni-
tored for 20 seconds to assure no pulmonary damage,
bleeding or pneumothorax. Suture of the skin can be
done with a continuous suture or clips.
Complications related to ICAPS
Analysis of intra- and post-operative complications dur-
ing the procedure revealed that the pleural space can be
approached in over 90% of cases without complications
(Table 1). I observed three major, but thereafter mostly
lethal complications:
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during insertion of the catheter into the pleural
space, the injected fluid will evacuate through
mouth and nose of the animal.
(ii) after puncturing the pleural space intra-pleural
bleeding (0.9%) can occur.
(iii)after removing the catheter from the pleural space a
pneumothorax (1.8%) can occur.
In case (i) the procedure should be terminated and the
mouse sacrificed. In case (ii) and (iii) proceeding with
the procedure depends on the severity of the bleeding
(ii) as well as the size of the pneumothorax (iii). In my
experience around 50% of the mice with type (ii) and
(iii) complications survived the procedure without con-
sequences. However, after skin closure and re-placement
of the mouse into the cage death of the mouse may
occur in the next 24 hours. No wound infection was ob-
served in any of the performed procedures.
Intra-pleural manipulation using the ICAPS model
Clodronate or PBS liposomes, Talcum or PBS were
injected. For depletion of the pleural space cells 1 ml
PBS was injected into the pleural space and removed
after 30 seconds by careful aspiration through the
inserted catheter. This was performed twice. To sup-
press pleural B cell function 200 μg of neutralizing anti-
mouse IgM antibody (GENWAY, GWB-5A60E2) in
200 μl PBS was injected intra-pleurally.
Experimental design
Regarding to the purpose of the experiment, the timing
of performing ICAPS and altering the pleural space
microenvironment with one of the below mentioned
techniques is essential. For example, targeting the
macrophage population and investigating their contribu-
tion and importance during infectious diseases (e.g. by
intra-tracheal injection of Staphylococcus pneumoniae,
Escherichia coli, Klebsiella pneumoniae) the injection of
clodronate liposomes will deplete the entire macrophage
population within 24 hours. Therefore, ICAPS would
need to be performed 24 hours before induction of the
airway infection. Although ICAPS is a small surgical
procedure, the insertion of a catheter into the pleural
space may cause alterations of the microenvironment.
To control for this during experimental procedures I
suggest performing ICAPS in the control group and in-
ject sterile fluid (PBS or saline).
Additional animal models and in vivo interventions
Pneumonia models: Animals were infected intra-nasally
or intra-tracheally with 20 μg LPS or 5 × 106 CFU
Escherichia coli (ATCC # 25922) in a volume of 50 μl sa-
line. Clinical score: The clinical score of each animal wasassessed as follows (points). [a] appearance: normal (0),
lack of grooming (1), piloerection (2), hunched up (3),
above and eyes half closed (4); [b] behaviour - unpro-
voked: normal (0), minor changes (1), less mobil and iso-
lated (2), restless or very still (3); behaviour - provoked:
responsive and alert (0), unresponsive and not alert (3);
[c] clinical signs: normal respiratory rate (0), slight
changes (1), decreased rate with abdominal breathing
(2), marked abdominal breathing and cyanosis (3); [d]
hydration status: normal (0), dehydrated (5). The higher
the score the worse the clinical situation of the animal.
Temperature: The temperature of each animal was mea-
sured by rectal insertion of a temperature sensor while
the mouse was under anesthesia.
Bacteria
Broncho-alveolar lavage (BAL) samples were diluted,
plated on tryptic soy agar (BD Difco), and incubated at
37°C. The number of bacterial colonies was assessed
12–14 h later.
Murine Leukocytes
Peripheral blood for flow cytometry was collected by
aortic puncture, using a 50 mM EDTA solution as anti-
coagulant. Erythrocytes were lysed using RBC Lysis
Buffer (BioLegend). Total white blood cell count was ob-
tained by preparing a 1:10 dilution of (undiluted) periph-
eral blood from the orbital sinus using heparin-coated
capillary tubes in RBC Lysis Buffer (BioLegend). After
organ harvest, single cell suspensions were obtained as
follows: lungs were cut into small pieces and subjected
to enzymatic digestion with 450 U/ml collagenase I, 125
U/ml collagenase XI, 60 U/ml DNase I and 60 U/ml hy-
aluronidase (Sigma-Aldrich, St. Louis, MO) for 1 h at
37°C while shaking. Lungs were then homogenized
through a 40 μm nylon mesh. Lymph nodes were ho-
mogenized through a 40-μm nylon mesh, after which
erythrocyte lysis was performed using RBC Lysis Buffer
(BioLegend). The pleural space was lavaged with 2 × 1 ml
of PBS to retrieve leukocytes. Broncho-alveolar lavage
(BAL) was performed by flushing the lungs with 4 × 1 ml
of PBS to retrieve the infiltrated and resident leukocytes.
Single-cell suspensions were prepared. Total viable cell
numbers were obtained using Trypan Blue (Cellgro,
Mediatech, Inc, VA).
Flow cytometry
The following antibodies were used for flow cytometric
analyses: anti-CD43-FITC, S7 (BD Biosciences); anti-
Ly6C-FITC, AL-21 (BD Biosciences); anti-IgM-FITC,
II/41 (BD Biosciences); anti-CD3e-FITC, 145-2C11
(BD Biosciences); anti-B220-PE, RA3-6B2 (BD Biosciences);
anti-CD19-PE, 1D3 (BD Biosciences); anti-NK1.1-PE,
PK136 (BD Biosciences); anti-CD49b-PE, DX5 (BD
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anti-Ly6G-PE, 1A8 (BD Biosciences); anti-Ter119-PE,
TER-119 (BD Biosciences); anti-CD43-PE, S7 (BD Biosci-
ences); anti-IgM-PerCPCy5.5, R6-60.2 (BD Biosciences);
anti-MHCII-PerCPCy5.5, AF6-120.1 (BioLegend); anti-
CD11c-PerCPCy5.5, HL3 (BD Biosciences); anti-CD8-
PerCPCy5.5, 53–6.7 (BD Biosciences); anti-CD5-PECy7,
53–7.3 (eBioscience); anti-CD90.2-PECy7, 53–2.1 (BD
Biosciences); anti-F4/80-PECy7, BM8 (BioLegend); anti-
IgM-APC, II/41 (Bd Biosciences); anti-CD43-APC, S7 (BD
Biosciences); anti-Ly6C-APC, AL-21 (BD Biosciences);
anti-CD25-APC, PC61 (BD Biosciences); anti-MHCII-
Alexa Fluor 700, M5/114.15.2 (eBioscience); anti-CD4-
Alexa Fluor 700, GK1.5 (eBioscience); anti-CD19-APCCy7,
6D5 (BioLegend); anti-CD11b-APCCy7, M1/70 (BD Bio-
sciences); anti-IgM-APCCy7, RMM-1 (BioLegend); anti-
CD45.2-Pacific blue (BD Biosciences); anti-CD19-Brilliant
Violet 421, 6D5 (BioLegend); anti-IgM-Brilliant Violet
421, RMM-1 (BioLegend); anti-CD11b-Brilliant Violet
421, M1/70 (BioLegend). B cell populations were identi-
fied as described previously [21]. Data were acquired on a
LSRII (BD Biosciences) flow cytometer and analyzed with
FlowJo v8.8.6/v9.7.2 (Tree Star, Inc.).
Statistics
Results were expressed as means ± S.D. Statistical tests
included unpaired, 2-tailed Student's test using Welch's
correction for unequal variances and 1-way ANOVA
followed by Tukey’s or Newman-Keuls Multiple Com-
parison Test. P values of 0.05 or less were considered to
denote significance.
Results
Flushing of the pleural space and its cellular repopulation
After inventing ICAPS I wondered if the pleural space
cellular environment can be depleted without perman-
ently harming the pleural space microenvironment and
to mimic the postoperative situation in patients treated
with chest tubes. I therefore flushed the pleural space
twice with 1.0 ml sterile PBS and was able to deplete all
cellular compartments from the pleural space within
1 day. Analysis of the percentages and total amount of
pleural space cells revealed that almost all pleural space
macrophages were depleted within 1 day after flushing
(Figure 2A). The repopulation of pleural space macro-
phages was gradually reaching steady state conditions
7 days after flushing. Interestingly, analysis of B and T
cells revealed no dramatic percentage changes over the
course of 7 days (Figure 2B). However, their amount did
change dramatically on day 1 after flushing due to deple-
tion of all cellular compartments (Figure 2C). This pro-
cedure can be performed without harming the pleural
space environment and is an effective tool to temporarily
deplete all cells from the pleural space.Alteration of the pleural space cellular environment
For a better understanding of the biological contribution
of immune cells during different diseases the cells of
interest often need to be depleted, activated or altered
during experiments. A variety of these techniques are
well characterized [22-26]. Here I present three add-
itional approaches to alter the pleural space microenvir-
onment. The steady state environment of the pleural
space contains mostly B and T cells and macrophages
(Figure 2). Injection of clodronate liposomes leads to the
depletion of all pleural space macrophages (Figure 3A).
This procedure had no major effects on the monocyte or
macrophage subsets in other compartments. Although
the amount of total cells increased significantly after clo-
dronate injection (Figure 3B) the percentage (Figure 3C)
and total amount (Figure 3D) of macrophages decreased.
Hence, by injection of clodronate liposomes i.pls. the
pleural space macrophages can be specifically depleted.
By flushing the pleural space twice with 1.0 ml sterile
PBS, all cellular compartments can be depleted without
damaging the pleural spaces’ biological or physiological
function (Figure 2). Flushing leads to a repopulation of
pleural space cells similar to the situation that patients
encounter after removal of the chest tubes. By injection
of Talcum, all cellular compartments can be depleted
within 1 day and results in a permanent depletion of all
cells in the pleural space (Figure 3).
Effects of targeted versus complete cellular depletion of
the pleural space
Recent studies revealed that chest tubes increase the
risk for airway infection [20]. I wondered if either de-
pletion of pleural space macrophages or depletion of
the entire pleural space cellular microenvironment can
alter the course of airway infection. To evaluate this I
analyzed the broncho-alveolar lavage (BAL) during
steady state and 1 day after LPS i.n. challenge. During
steady state conditions, neither intra-pleural injection
of clodronate liposomes nor flushing of the pleural
space had significant impact on the amount of immune
cells in the BAL (Figure 4). However, after flushing of
the pleural space, an increased influx of CD11b+ cells
(Figure 4A) and neutrophils (Figure 4B) into the BAL
was observed 1 day after LPS i.n challenge. Interest-
ingly, depletion of pleural space macrophages by i.pls.
injection of clodronate liposomes one day prior to LPS
i.n. challenge had no impact on the amount of infiltrat-
ing CD11b+ cells and neutrophils as compared to con-
trols. Analysis of the BAL revealed decreased amounts
of linage cells (T cells, NK cells, B cells) only after
flushing of the pleural space, but no effect was ob-
served after i.pls. injection of clodronate liposomes
(Figure 4C). I therefore hypothesized that the pleural
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Figure 2 Time of repopulation of the pleural space cells after flushing by using ICAPS. (A) Percentages of pleural space macrophages in
steady state and 1, 2, 4 and 7 days after flushing of the pleural space with PBS reveals an at least 7 day repopulation time. A representative
analysis is shown. (B) Percentages of CD3+ T cells and CD19+ B cells are shown. A representative analysis is shown. (C) Analysis of the total cell
numbers in steady state and 1, 2, 4, and 7 days after flushing of the pleural space reveals that pleural space macrophages need 7 days to
repopulate the pleural space. T and B cells repopulate within 2 days after flushing. (n = 6; data shown in means ± S.D.; ***p < 0.001).
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acute immune response during airway inflammation.
Pleural space B1a B cells redistribute into the lungs
during airway inflammation
Based on the presented results, I tested for the immuno-
logical contribution of pleural space cells during airway
inflammation. During steady state, the pleural space
consists of several different cell types including mono-
cytes and neutrophils, macrophages, T cells and B cells.
Thereby, B1a B cells account for the largest cell subset
(Figure 5A). I therefore sought to enumerate the amount
of pleural space B1a B cells during a three day LPS i.n.
challenge. Pleural space B1a B cells decreased signifi-
cantly each day whereas the amount of B1a B cells in-
creased in the lung parenchyma. No changes were found
in the blood that consisted only of very few B1a B cells
(Figure 5B). So far, the presented results indicate that
pleural space linage cells (T cells, NK cells, B cells) and
especially B1a B cells may redistribute into areas of ac-
tive inflammation. To directly test for this I used ICAPSand flushed the pleural space of wt mice to deplete the en-
tire pleural space cellular microenvironment (Figure 5C).
In wt mice, B1a B cells decreased significantly in the
pleural space and increased significantly in the lungs 1 day
after LPS i.n. challenge. In contrast, after flushing of the
pleural space leading to the entire depletion of all pleural
space cells, including B1a B cells, no increase of the B1a B
cells in the lungs 1 day after LPS i.n. challenge was ob-
served suggesting that B1a B cells redistribute from the
pleural space into the lungs upon airway inflammation
(Figure 5C). Enumeration of B1a B cells during steady
state conditions and 1 day after LPS i.n. challenge revealed
a significant increase of B1a B cells in the draining thor-
acic lymph nodes but no changes in other compartments
(Figure 5D).
Suppression of pleural space B cell function leads to
decreased bacterial clearance
Patients that underwent thoracic surgery regularly
require chest tubes to evacuate wound fluid and air from






































































































































Figure 3 Altering of the pleural space cellular environment. (A) The pleural space contains CD11b+F4/80+ macrophages in the steady state.
By using ICAPS injection of clodronate liposomes i.pls., flushing the pleural space with saline, or injection of talcum i.pls. leads to the removal of
CD11b+F4/80+ macrophages 1 d after the procedure. A representative analysis is shown. (B) Total cell numbers significantly increase after
injection of clodronate liposomes, and significantly decrease after flushing the pleural space or injection of talcum into the pleural space. The
percentage (C) and enumeration (D) of CD11b+F4/80+ pleural space macrophages reveal their deletion within 1 day (n = 5; data shown in
means ± S.D.; ***p < 0.001).
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procedure, the immunologic microenvironment of the
pleural space may be compromised. As a consequence,
the susceptibility to airway infection can increase. I have
already shown that depletion of the entire pleural space
leads to an increase in neutrophilic influx into the BAL
during airway inflammation. Recently, we have shown
that B1a B cells, the major producers of natural IgM and


































Figure 4 Depletion of the pleural space cellular environment increa
inflammation. Cellular enumeration of (A) CD11b+ linage−(CD19+B220+
+CD11b+ MHCII−CD11c−F4/80−Ly6Cint.), and (C) linage+CD11b− cells 1 d
pleural space and in control mice. (n = 4-6; data shown in means ± S.D.;into the lungs during airway inflammation and may there-
fore function as an important source for protective im-
munity [27]. I wondered to which extent the pleural space
is responsible for an sufficient protection during bacterial
airway infection. To analyze the importance of pleural
space B1a B cells most accurately I injected neutralizing
anti-mouse IgM antibody into the pleural space of wt
mice 6 hours prior to induction of bacterial pulmonary in-
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Figure 5 B1a cells evacuate the pleural space upon airway inflammation into the lungs. (A) Gating strategy of pleural space B1a B cells in
the steady state. A representative analysis is shown. (B) Enumeration of B1a B cells in steady state, and 1, 2, and 3 days after LPS (20 μg/50 μl) i.n.
challenge in the pleural space, the lungs and the blood in wt mice. (C) Enumeration of B1a B cells in the pleural space and lungs 1 d after LPS
(20 μg/50 μl) i.n. challenge with or without flushing of the pleural space. (D) Enumeration of B1a B cells during steady state and 1 d after LPS
(20 μg/50 μl) i.n. challenge in lymph nodes (LN), spleen, bone marrow (BM), and blood. (n = 5-8; data are shown in means ± S.D.; *p < 0.05;
**p < 0.01; ***p < 0.001).
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space. Compared to controls, i.pls. injection of neutraliz-
ing anti-mouse IgM antibody resulted in significantly in-
creased clinical scoring and reduced body temperature
indicating a more severe pulmonary infection (Figure 6B)
9 hours after induction of pulmonary infection. Bacterial
counts in the broncho-alveolar lavage fluid revealed a de-
creased ability to clear bacterial infection after i.pls. injec-
tion of neutralizing anti-mouse IgM antibody compared
to controls (Figure 6C). The results indicate that alteringE.coli
i.t.





















Figure 6 Suppression of pleural space B cell function by neutralizing
bacterial clearance. (A) Intra-pleural injection of neutralizing anti-mouse I
Escherichia coli (5×106 CFU) airway infection with analysis after 9 hrs of infe
BAL. (n = 10; data are shown in means ± S.D.; *p < 0.05; **p < 0.01; ***p < 0.the immune function of pleural space B cells has impact
on the hosts ability to fight airway infection.
Discussion
The results presented here identify the ICAPS model as
useful technique in altering the pleural spaces’ cellular
environment. ICAPS allows to deplete pleural space cells
partially or completely as well as temporarily or perman-
ently. The results further reveal that depletion of pleural



















anti-mouse IgM antibody leads to reduced broncho-alveolar
gM antibody or IgG isotype control into wt mice and intra-tracheal (i.t.)
ction. (B) Clinical score and body temperature. (C) Bacterial titre in the
001).
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that altering their biological function leads to impaired
host defense.
Our understanding of the contribution of pleural space
cells during health and disease is still rudimentary. One
major obstacle was the lacking possibility to experimen-
tally investigate their immunological function. During
infectious, malignant, autoimmune and allergic diseases
- all of which alter the bodies immune response in dif-
ferent time frames - the pleural space might function as
a source of immune-competent cells which influence the
course of disease.
Much biology on pleural leukocytes has been inferred,
but data are lacking on the cells’ in vivo behavior and
their contribution to airway disease. I therefore devel-
oped a new technique that I named the “InterCostal
Approach of the Pleural Space” (ICAPS) to approach the
pleural space of rodents in vivo. Insertion of a small
catheter through the intercostal space in a low angle
avoids severe complications. Bypassing the diaphragm
allows thereby for a fast and easy-to-learn method to ap-
proach the pleural space (researchers as well as techni-
cians are able to learn ICAPS within 1 day).
The experimental approach using the ICAPS model
gives supporting evidence that the pleural space func-
tions as a hub for immune cells that contribute to the
immune response during airway inflammation and infec-
tion. By using ICAPS I altered the immune function of
the pleural space: (i) Flushing of the pleural space led to
the depletion of the entire cellular microenvironment in-
cluding macrophages, T cells and B cells mimicking the
postoperative chest tube treatment after thoracic sur-
gery. (ii) Injection of neutralizing anti-mouse IgM anti-
body led to suppression of pleural space B cell function.
Although these models do not represent the postopera-
tive situation perfectly, both approaches resulted in an
impaired control of inflammation and infection which
indicates in part the cellular contribution of pleural
space cells during inflammatory airway disease.
The results suggest that depletion of B1a B cells rather
than macrophages lead to impaired control of airway in-
flammation. The reason for this could be that the pleural
space functions as a source for innate like B cells [10]
which participate in the early innate immune response
during airway infection. Recently, we described an im-
portant role of the pleural space as a hub of IgM produ-
cing B1/IRA B cells that migrate from the pleural space
into the lung during airway infection [27]. However, to
which impact these cells redistribute from the pleural
space into the airways remains elusive. The fact that in-
nate like B cells are detectable in only very few amounts
in the circulating system makes it likely that pleural
space innate like B1a B cells contribute in an immune-
physiological context to inflammatory adjacent organsand altering their function may have impact on the bod-
ies protective immune function during inflammatory air-
way disease. Thus, immune targeting and activation of
pleural space cells itself may increase the hosts capacity
to control infection. This might have impact on the de-
sign for clinical studies investigating the function of
pleural space immune cells which could lead to new
therapeutic interventions for patients with pulmonary
diseases.
Conclusion
Pleural space cells may be involved in several diseases.
For a better understanding of their contribution, ICAPS
could serve as a widely-used model and could help to
answer critical questions of immune cell trafficking from
the pleural space to adjacent organs (lungs, lymph
nodes, heart, thymus, etc.) as well as answer questions
regarding the pleural space cells’ contribution during the
course of pulmonary acute and chronic diseases (malig-
nant, inflammatory, autoimmune, allergic).
Additional file
Additional file 1: Video Visualisation of the ICAPS model. The video
describes the technique of the ICAPS model in rodents. Exemplary, the
technique is shown on a mouse.
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